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Elevated serum and cerebrospinal ﬂuid concentrations of S100b, a protein predominantly found in glia,
are associated with intracranial injury and neurodegeneration, although concentrations are also inﬂu-
enced by several other factors. The longitudinal association between serum S100b concentrations and
brain health in nonpathological aging is unknown. In a large group (baseline N ¼ 593; longitudinal N ¼
414) of community-dwelling older adults at ages 73 and 76 years, we examined cross-sectional and
parallel longitudinal changes between serum S100b and brain MRI parameters: white matter hyper-
intensities, perivascular space visibility, white matter fractional anisotropy and mean diffusivity (MD),
global atrophy, and gray matter volume. Using bivariate change score structural equation models, cor-
recting for age, sex, diabetes, and hypertension, higher S100b was cross-sectionally associated with
poorer general fractional anisotropy (r ¼ 0.150, p ¼ 0.001), which was strongest in the anterior thalamic
(r ¼ 0.155, p < 0.001) and cingulum bundles (r ¼ 0.111, p ¼ 0.005), and survived false discovery rate
correction. Longitudinally, there were no signiﬁcant associations between changes in brain imaging
parameters and S100b after false discovery rate correction. These data provide some weak evidence that
S100b may be an informative biomarker of brain white matter aging.
 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The calcium-binding protein S100b has clinical value as a
proteomic biomarker of central nervous system damage. It is
primarily found in glial cells, but also in some neuronalogy, The University of Edin-
0131 650 8493; fax: 0131 651
Inc. This is an open access articlepopulations and in melanocytes, among other cell types (Donato,
2006; Donato et al., 2013). At nanomolar concentrations, S100b
exerts neuroprotective and neurotrophic inﬂuences, but elevated
S100b may contribute to further negative effects, as its presence
at micromolar concentrations increases expression of proin-
ﬂammatory cytokines, leading to apoptosis (Kleindienst et al.,
2010; Rothermundt et al., 2003; Steiner et al., 1999). S100b is
elevated after traumatic brain injury in both cerebrospinal ﬂuid
(CSF) and serum (Ingebrigtsen and Romner, 2002; Petzold et al.,
2003; Vos et al., 2010), with greater S100b concentrationsunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Thelin et al., 2017). Serum S100b levels are also inﬂuenced by
blood-brain barrier (BBB) leakage (Kapural et al., 2002;
Kleindienst et al., 2010; Ucar et al., 2004), as well as from other
sources such as bone fractures, exercise, muscle injury, burns and
melanoma (Anderson et al., 2001; Harpio and Einarsson, 2004;
Koh and Lee, 2014; Mocellin et al., 2008; Mohammed et al.,
2001; Pelinka et al., 2003).
Although S100b has been investigated as a biomarker (in
serum and CSF) in studies of head injury, depression, and
neurodegenerative diseases such as Alzheimer’s disease (Chaves
et al., 2010; Peskind et al., 2001; Polyakova et al., 2015), the
neurostructural correlates of S100b and its longitudinal trajec-
tories in nonpathological aging are underinvestigated. S100b
concentrations are positively associated with age (Nygaard et al.,
1997; Schroeter et al., 2011; van Engelen et al., 1992), although
some (Portela et al., 2002; Wiesmann et al., 1998) found no age
effect in adulthood. Identifying possible biomarkers of brain ag-
ing is a key challenge (Academy of Medical Sciences, 2016;
Jylhävä et al., 2017), and serum S100b is one of the logical can-
didates, yet data on S100b and multimodal brain analyses in older
participants are lacking. Two prior cross-sectional studies indi-
cate that serum S100b is speciﬁcally associated with poorer white
matter microstructure (assessed with diffusion tensor MRI) in a
small sample of healthy participants (N ¼ 41, effect found in fe-
males only; Streitbürger et al., 2012), and in a small study of
schizophrenia patients versus controls (total N ¼ 39; Milleit et al.,
2016). Neither study found a signiﬁcant association between
S100b and gray matter (GM)dhowever, it should be noted that
both adopted a voxel-basedemorphometry approach which re-
sults in reduced power in the large areas of the cortex that show
highly individualized patterns of gyriﬁcation, and insensitivity to
discrete lesions; Tisserand et al., 2004). Another study (N ¼ 102;
van der Leeuw et al., 2017) found no association between S100b
and either white matter fractional anisotropy (FA) or cortical
thickness in a mixed sample of patients with psychosis, relatives,
and controls. Thus, well-powered, longitudinal, multimodal im-
aging studiesdin participants at an age that confers relatively
high risk of brain structural declinedare required to examine the
possible differential sensitivity of S100b to cross-sectional levels
of, and longitudinal declines in, various imaging parameters and
brain tissues.
Other candidate MRI parameters that may relate to S100b are
markers of cerebral small vessel disease (SVD) burden. There is
increasing evidence that BBB leakage occurs as an underlying
pathology in SVD (Wardlaw et al., 2017; Zhang et al., 2017). The
presence of white matter hyperintensities (WMHs) and peri-
vascular spaces (PVS) are important markers of SVD pathophys-
iology that increase with age, in cerebrovascular disease, are
linked to increased risk of stroke, and are associated with both
cognitive impairment and dementia (Doubal et al., 2010;
Wardlaw et al., 2015). PVS are also associated with elevated
plasma markers of inﬂammation in older participants (Aribisala
et al., 2014). They are also more frequent in patients with
lacunar stroke and WMH, and are more visible with increasing
evidence of BBB leakage in patients with SVD-related stroke
(Wardlaw et al., 2009). PVS are also more visible with inﬂam-
mation and BBB leakage in active multiple sclerosis plaques
(Wuerfel et al., 2008). Although plasma S100b is inﬂuenced by
BBB leakage in head injury as well as general cerebral pathology,
it remains unknown whether S100b is associated with these
important SVD markers on brain MRI in healthy community-
dwelling older adults.
In the present study, we investigated the level and change in
S100b and indices of structural and diffusion MRI, in a largecohort of older individuals measured at ages 73 and 76 years.
Given that S100b concentration in blood may rise due to age,
central nervous system (CNS) damage, and BBB disruption, we
hypothesized that relatively higher and increasing concentrations
of plasma S100b would be coupled with lower and decreasing
measures of brain structural and microstructural health. Prior
evidence indicates that S100b is particularly strongly expressed
in the human brain’s white matter tracts (histological data
showed co-localization of S100b with oligodendrocyte markers in
the human brain; Streitbürger et al., 2012), and that serum S100b
is cross-sectionally associated with poorer white matter micro-
structure (assessed with diffusion tensor MRI) in small mixed
samples (N  102) with wide age ranges (Milleit et al., 2016;
Streitbürger et al., 2012). Thus, we hypothesize that elevated
and increasing serum S100b would be particularly pertinent to
poorer and decreasing white matter structure, beyond measures
of global atrophy and GM volume.
2. Materials and methods
2.1. Participants
Data are drawn from waves 2 and 3 of a longitudinal study of
aging: the Lothian Birth Cohort 1936 study (LBC1936; Deary
et al., 2007; 2012), when participants were a mean age of
about 73 and 76 years, respectively. In 1947, Scotland tested the
intelligence of almost all schoolchildren born in 1936, and the
LBC1936 follows up some of those individualsdnow in older
agedwho mostly live in the Edinburgh and Lothians area. The
initial wave of LBC1936 (wave 1) took place between 2004 and
2007. It assessed 1091 individuals on aspects of their health, and
physical and cognitive function, at around 70 years old (M ¼
69.53, SD ¼ 0.832). At wave 2 (2007e2011) and wave 3
(2011e2013), 866 and 697, respectively, returned at mean ages
of about 73 and 76 years, a detailed MRI brain scan was added to
the protocol at both waves (Wardlaw et al., 2011). During a
medical interview at each wave, participants reported their
medical history (including a self-reported diagnosis of hyper-
tension, diabetes, melanoma, and dementia). The Multi-Centre
Research Ethics Committee for Scotland (MREC/01/0/56), the
Scotland A Research Ethics Committee (07/MRE00/58), and the
Lothian Research Ethics Committee (LREC/2003/2/29) approved
the use of the human participants in this study; all participants
provided written informed consent and these have been kept on
ﬁle.
2.2. S100b
Serum samples were obtained from participants during the
main physical and cognitive testing appointment at waves 2 and 3.
The mean lag between waves was 3.77 years (SD ¼ 0.28). After
collection, samples were stored at 80 C at the Wellcome Trust
Clinical Research Facility, Western General Hospital, Edinburgh,
until the conclusion of the wave. They were then transferred to the
Department of Clinical Biochemistry, King’s College London using
cold-chain logistics, where they were stored at 20 C until assays
were conducted using a chemiluminescence immunoassay S100b
kit (distributed by DiaSorin, Berks, UK) on a LIAISON chem-
iluminescence analyzer. The lag between sample dispatch at the
end of sampling and assay completion (i.e., time stored at 20 C
rather than 80 C) was an average of 44 days (SD ¼ 26) for 4
batches at wave 2, and 8 days (single batch) at wave 3, respectively.
The minimal detectable concentration of the assay was 0.02 mg/L.
Intra- and inter-assay precision for both waves is reported in
Supplementary Table A.1.
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Participants underwent whole-brain structural and diffusion
MRI using the same 1.5 T GE Signa Horizon scanner (General
Electric, Milwaukee, WI, USA) at wave 2 and 3. The scanner is
maintained with a careful quality control programme. Scans took
place at the Brain Research Imaging Centre, Edinburgh, shortly after
serum collection (mean lag for the present study sample: wave
2 M ¼ 65.39 days, SD ¼ 34.69; wave 3 M ¼ 38.69 days, SD ¼ 28.37).
Full details of acquisition and processing are available in an open
access protocol article (Wardlaw et al., 2011). Brieﬂy, T1-, T2-, T2*-,
and FLAIR-weighted sequences were co-registered (voxel size¼ 1
1  2 mm). Total brain (TB), GM, and white matter hyperintensity
volumes were quantiﬁed using a semiautomated multispectral
fusion method (Valdés Hernández et al., 2010). WMHs were
explicitly deﬁned as punctate, focal, or diffuse lesions in subcortical
regions and distinguished from lacunes and PVS by signal charac-
teristics (Wardlaw et al., 2013). Cortical or discrete subcortical in-
farcts were excluded by careful manual editing blind to other
features. PVS were deﬁned as ﬂuid-containing small spaces running
parallel with the expected direction of perforating vessels,
appearing punctate in cross section and linear in longitudinal sec-
tion, with <3 mm diameter. PVS were differentiated from lacunes
or WMH on morphology, signal, and size criteria as previously
deﬁned (Wardlaw et al., 2013; Potter et al., 2015a). From the T2-
weighted volumes, PVS ratings were performed by a trained
neuroradiologist (JMW, ZM; Potter et al., 2015a; Potter et al., 2015b).
Change in PVS between waves was scored by comparing scans at
wave 2 and wave 3 side by side, blind to any other participant
characteristics, and scored on a 5-point scale from 2 (reduction,
i.e., improvement) to þ2 (increase, i.e., worsening), where 0 de-
notes no visible change.
The diffusion tensor MRI (DT-MRI) acquisition comprised a
single-shot spin-echo echo-planar diffusion weighted volumes
(b ¼ 1000 s mm2) acquired in 64 noncollinear directions,
alongside 7 T2-weighted images (b ¼ 0 s mm2). This yielded 72
contiguous axial slices (FoV ¼ 256  256 mm, matrix 128  128,
2 mm isotropic voxels). Repetition and echo times were 16.5 s and
95.5 ms, respectively. After preprocessing (brain extraction,
removal of bulk participant motion and eddy currenteinduced
distortions), water diffusion tensor parameters were estimated
using FSL tools (FMRIB; Oxford, UK; http://www.fmrib.ox.ac.uk). A
2-ﬁber model with 5000 streamlines was then used to create brain
connectivity data using the BEDPOSTX/ProbTrackX algorithm in 12
tracts of interest: the genu and splenium of the corpus callosum,
bilateral anterior thalamic radiation, cingulum, uncinate, arcuate,
and inferior longitudinal fasciculi. Probabilistic neighborhood
tractography as implemented in the TractoR package (http://www.
tractor-mri.org.uk; Clayden et al., 2011) identiﬁed the tracts of
interest from the connectivity data (Bastin et al., 2010; Muñoz
Maniega et al., 2017). White matter tract-averaged FA and mean
diffusivity (MD) were then derived as the average of all voxels
contained within the resultant tract maps. All segmented images
were visually inspected for accuracy, blind to participant charac-
teristics, to identify and correct errors.
2.4. Statistical analysis
We excluded from the analyses those with self-reported his-
tory of dementia, or Mini-Mental State Examination score of <24
(n ¼ 35). This was based on prior reports of elevated S100b in
dementia (Chaves et al., 2010), the likelihood that these in-
dividuals were undergoing pathological CNS degeneration, and
their low numbers in the current cohort (yielding low statistical
power with which to reliably detect associations). Given thatelevated serum S100b is associated with melanoma (Harpio and
Einarsson, 2004; Mocellin et al., 2008; Mohammed et al., 2001),
those who reported melanoma at either wave (n ¼ 26) were also
excluded. S100b concentrations for excluded participants are
shown in Supplementary Table A.2. Both WMHmeasures were log
transformed to correct skewness. Extreme outlying points (>4 SDs
above the mean) for S100b at wave 2 (n ¼ 6) and wave 3 (n ¼ 4)
were removed, along with 7 points at wave 3 that were below the
sensitivity threshold of the assay (<0.02 mg/L). After exclusions, a
total of 776 and 619 participants provided S100b data at ages 73
and 76 years, respectively, 593 and 414 of whom also provided
brain MRI data. We used the maximum available sample size in all
analyses.
The main questions we addressed were (1) are there associ-
ations between serum S100b and brain imaging variables cross-
sectionally at age 73 years? and (2) are the changes in S100b
from age 73 years to age 76 years correlated with changes in
brain imaging variables across the same ages? We used bivariate
change score models (McArdle, 2009) in a structural equation
modeling (SEM) framework to test these cross-sectional and
longitudinal associations between S100b and brain MRI variables
(Fig. 1), specifying a separate model for each brain MRI outcome.
In the case of PVS analysis, the visual rating of PVS change was
used in place of a latent change score, and correlated with the
latent S100b change score. The volumetric brain indices were
expressed as a proportion of intracranial volume in our main
SEMs, and we also provided a supplementary analysis for un-
corrected measures. Using the FA and MD measures across mul-
tiple white matter tracts, we derived a latent variable (hereafter
referred to as gFA and gMD) for waves 2 and 3, respectively, using
the following: genu and splenium of the corpus callosum, and
left-right averages of the anterior thalamic radiation, inferior
longitudinal fasciculus, uncinate, arcuate, and cingulum. We
imposed strong factorial invariance (as was previously shown to
be possible for these data; Ritchie et al., 2015), constraining the
intercepts of each tract measure and their loadings on the latent
variable to equality across waves. We also included correlated
residuals between corresponding tracts across waves, alongside 5
other signiﬁcant tract-tract residual paths for gFA and 6 for gMD.
This builds on our and others’ prior work, which found that there
is substantial shared variance in white matter microstructural
properties across tracts of the brain in early life, middle, and
older age (Cox et al., 2016; Penke et al., 2010; Ritchie et al., 2015;
Telford et al., 2017). Thus, these general, latent, factors reﬂect
common microstructural properties (FA and MD) across white
matter pathways. Finally, based on evidence of local white matter
variation in S100b expression (most strongly expressed in the
corpus callosum and cingulum bundle) and cross-sectional as-
sociations between FA and S100b (Streitbürger et al., 2012; Milleit
et al., 2016; van der Leeuw et al., 2017; Allen Institute for Brain
Science, 2010), we used the same framework as above to
examine associations between S100b and tract-speciﬁc micro-
structure in each white matter tract of interest for FA and MD.
Given that therewas a short delay between serum collection and
MRI scanning at both waves, we corrected MRI and S100b for their
respective age in days at data collection within each model, along
with sex, diabetes, and hypertension. To account for missing data
bias due to attrition betweenwaves, we took account of all available
data, using full information maximum likelihood estimation. We
assessed model ﬁt according to the c2 minimum function test sta-
tistic, the root mean square error of approximation (RMSEA),
comparative ﬁt index (CFI), Tucker-Lewis index (TLI), and the
standardized root mean square residual (SRMR). All statistical an-
alyses were conducted in R version 3.2.2 “Fire Safety” (R Core Team,
2015). SEM was conducted with the “lavaan” package (Rosseel,
A B
Fig. 1. Example of bivariate change score models. Baseline level of, and 3-year change in, S100b is associated with the wave 2 level and wave 2ewave 3 (age 73e76 years) change in
(A) a latent factorially invariant measure of FA, and (B) white matter hyperintensity volume. Individual tract-averaged values in (A) are A:G (correlated residuals not shown). For PVS
analysis, the visual rating of change replaces the MRI-based delta (DWMH, in this example). Manifest (observed) variables are corrected for age in days at serum collection at both
waves (Age2, Age3), and at the 2 MRI scans (AgeMRI2, AgeMRI3), which corrects for within-wave lag between serum and MRI collection. All observed variables are also corrected for
sex (not shown), with MRI data also corrected for diabetes and hypertension diagnoses (not shown). * denotes cross-sectional and longitudinal relations of interest. Abbreviations:
FA, fractional anisotropy; PVS, perivascular space rating; WMH, white matter hyperintensity. (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the Web version of this article.)
Table 1
Participant characteristics
Variable Units Wave 2 (age 73 y) Wave 3 (age 76 y)
Mean (SD) N Mean (SD) N
Sex M:F 395:381 776 314:305 619
Age S100b Years 72.493 (0.716) 776 76.243 (0.679) 619
S100b mg/L 0.085 (0.035) 776 0.092 (0.040) 619
MMSE /30 28.815 (1.285) 775 28.838 (1.291) 619
WMH cm3 8.060 (11.376)a 592 10.998 (15.542)a 413
Total Brain cm3 991.176 (90.522) 593 976.179 (91.483) 414
GM cm3 472.862 (44.860) 593 466.321 (43.753) 411
Descriptive MRI data are provided for those that gave S100b at the same wave.
Key: GM, gray matter volume; MMSE, Mini-Mental State Examination; WMH, white
matter hyperintensity volume (untransformed).
a Median and IQR provided for raw (untransformed) volumes.
S.R. Cox et al. / Neurobiology of Aging 69 (2018) 274e282 2772012) and the resultant p-values for the associations of interest (see
asterisks in Fig. 1) were corrected for multiple comparisons with
false discovery rate (FDR; Benjamini and Hochberg, 1995) using the
“p.adjust” function in R.
3. Results
3.1. Participant and S100b descriptives, and analysis of losses to
follow-up
Participant characteristics are shown in Table 1, and bivariate
associations among study variables are reported in Supplementary
Table A.3. Descriptive plots of S100b (density, and age 73e76 years
correlation, boxplot, and trajectory) are in Fig. 2. S100b concen-
trations showed substantial stability of individual differences from
age 73 years to age 76 years (Pearson’s r ¼ 0.585, p < 0.001). S100b
concentrations were signiﬁcantly higher at age 76 years than at age
73 years (when considering returners only: wave 2 S100b M ¼
0.085, SD ¼ 0.035; wave 3 S100b M ¼ 0.092, SD ¼ 0.040; t
(1190.70) ¼ 3.244, p ¼ 0.001, Cohen’s d ¼ 0.118). Males showed
lower S100b than females at both waves (wave 2: t (773.28) ¼
3.655, p < 0.001; wave 3: t (614.69), p ¼ 0.002), but did not exhibit
differences in their rate of change with age (p ¼ 0.546; Fig. 2).
When comparing baseline values of those who returned to
provide an S100b sample at age 76 years from those who did not,
there were no signiﬁcant differences for S100b (t (270.19) ¼ 0.115,
p ¼ 0.908), TB volume (t (167.74) ¼ 1.577, p ¼ 0.117), WMH volume
(t (152.70) ¼ 1.277, p ¼ 0.204). However, individuals who returned
at age 76 years had signiﬁcantly more GM at age 73 years than
nonreturners (t (174.00) ¼ 2.800, p ¼ 0.006). To satisfy the
assumption of missing at random (MAR; Rubin, 1976), under which
FIML operates, baseline GM volume was included as an auxiliary
variable (Schafer and Graham, 2002) when modeling associationsbetween S100b and all other imaging variables. Signiﬁcant in-
creases inWMH volume and white matter tract MD, and signiﬁcant
decreases in TB volume, GM volume, and white matter FA exhibited
by this cohort betweenwave 2 and 3 have been previously reported
elsewhere (Dickie et al., 2016; Ritchie et al., 2015). In the context of
the current sample, all brain measures showed statistically signif-
icant mean changes over time, considering only those who pro-
vided scans at both waves. There were signiﬁcant reductions in raw
TB (t (851.73)¼ 2.815, p¼ 0.005, Cohen’s d¼ 0.191) and GM volume
(t (844.37) ¼ 2.861, p ¼ 0.004, Cohen’s d ¼ 0.197), and increases in
WMH volumes (t (809.50) ¼ 4.267, p < 0.001, Cohen’s d ¼ 0.293).
The visual ratings of PVS change across waves showed that PVS load
either stayed consistent (N ¼ 426 received a score of 0) or became
worse over time (N ¼ 42 received a score of þ1). Those who pro-
vided S100b and did not undergo anMRI scanwere not signiﬁcantly
different from those who provided bothdat either wave 2 or wave
3d in terms of age, S100b concentrations, and Mini-Mental State
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Fig. 2. Density plot (A), scatterplot with regression line and 95% CIs (B), beanplot to show mean differences (points jittered for visualization) (C), and plot of individual proﬁles of
returners at Wave 3, colored by sex, to illustrate individual differences in trajectories of S100b (mg/L) change (D). (For interpretation of the references to color in this ﬁgure legend,
the reader is referred to the Web version of this article.)
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who undertook both elements of the study comprised a signiﬁcantly
larger proportion of males at wave 2 (c2 ¼ 5.708, p ¼ 0.017),
although not at wave 3 (c2 ¼ 2.303, p ¼ 0.129).
3.2. Cross-sectional and longitudinal associations between S100b
and global MRI
Individuals showed substantial variation in the degree to which
S100b and the continuous MRI indices changed over time, as indi-
cated by signiﬁcant slope variances (all p< 0.001); slopemeans and
variances from age- and sex-corrected univariate change score
models are reported in Supplementary Table A.4. Results of the SEM
analyses are shown in Table 2, with bias-corrected 95% conﬁdence
intervals from 1000 bootstraps. Model ﬁt statistics are shown in
Supplementary Table A.5. Models examining associations between
the level and change of S100b and volumetric MRI indices showed
adequate ﬁt to the data (WMH: c2(28) ¼ 42.629, RMSEA ¼ 0.023,
CFI ¼ 0.993, TLI ¼ 0.988, SRMR ¼ 0.026; GM: c2(24) ¼ 42.337,
RMSEA¼ 0.027, CFI¼ 0.987, TLI¼ 0.977, SRMR¼ 0.022; TB volume:
c2(28) ¼ 131.237, RMSEA ¼ 0.060, CFI ¼ 0.931, TLI ¼ 0.887, SRMR ¼
0.039). None of these measures showed signiﬁcant cross-sectionalassociations with S100b at age 73 years (all absolute r-values
0.061, all p-values 0.113) or longitudinally (all absolute r-values
0.082, all p-values 0.095). Running these volumetric analyses
without correction for intracranial volume did not substantially
alter the results (Supplementary Table A.6). The model of visually
rated PVS change showed an adequate ﬁt to the data (c2(14) ¼
39.439, RMSEA ¼ 0.042, CFI ¼ 0.963, TLI ¼ 0.936, SRMR ¼ 0.032).
There was no association between S100b at age 73 years and
visually rated PVS change (r ¼ 0.034, p ¼ 0.475), and the nomi-
nally signiﬁcant associationwith longitudinal S100b concentrations
(r ¼ 0.096, p ¼ 0.041) did not survive FDR correction.
The models examining associations of S100b with white matter
diffusion parameters both ﬁtted the data well (gFA: c2(205) ¼
284.004, RMSEA ¼ 0.019, CFI ¼ 0.977, TLI ¼ 0.969, SRMR ¼ 0.035
and gMD: c2(205) ¼ 322.817, RMSEA ¼ 0.024, CFI ¼ 0.970, TLI ¼
0.959, SRMR ¼ 0.048); tract loadings are reported in
Supplementary Table A.7. At wave 2, higher S100b was signiﬁcantly
associated with “less healthy” white matter gFA (i.e., poorer direc-
tional coherence ofwatermolecular diffusion; r¼0.150, p¼ 0.001),
which survived correction for multiple comparisons. The 3-year
association between declining gFA and increasing S100b was
nonsigniﬁcant (r ¼ 0.083, p ¼ 0.154). Associations between gMD
Table 2
Cross-sectional (age 73 y) and longitudinal (age 73 y to age 76 y) associations between S100b and MRI variables
Variable Cross-sectional
(age 73 y)
95% CI Longitudinal
(age 73e76 y)
95% CI
Lower Upper Lower Upper
WMHa 0.019 (0.634) 0.092 0.074 0.082 (0.095) 0.002 0.174
PVS 0.034 (0.475)b 0.132 0.050 0.096 (0.041)b 0.183 0.007
gFA 0.150 (0.001) 0.233 0.065 0.083 (0.154) 0.199 0.038
gMD 0.003 (0.941) 0.099 0.114 0.019 (0.717) 0.135 0.075
GM 0.061 (0.133) 0.021 0.127 0.050 (0.309) 0.138 0.049
TBV 0.045 (0.272) 0.024 0.125 0.044 (0.364) 0.136 0.044
Data are shown as standardized coefﬁcients (p values), with bootstrapped 95% conﬁdence intervals (CIs) from 1000 draws.
Bold text indicates FDR q < 0.05.
Key: FDR, false discovery rate; gFA, general factor of white matter tract fractional anisotropy; gMD, general factor of white matter tract mean diffusivity; GM, gray matter
volume; PVS, perivascular space rating; TBV, total brain volume; WMH, white matter hyperintensity volume.
a log transformed.
b coefﬁcients are for associations between visually rated PVS change (rather than a latent change score) with S100b level and change.
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and change (r ¼ 0.019, p ¼ 0.717).
3.3. Cross-sectional and longitudinal associations between S100b
and white matter tract-speciﬁc microstructure
Next, we examined the level and change associations between
S100b and average white matter microstructure (FA and MD)
within each of the tracts of interest. Fit statistics indicated that all
models ﬁtted the data well (Supplementary Tables A.8 and A.9).
Results of the models are shown in Fig. 3, and Supplementary
Tables A.10 and A.11. A higher concentration of S100b at age 73
years was signiﬁcantly associated with “poorer” FA at the same age
in the anterior thalamic radiation (r ¼ 0.155 p < 0.001) and
cingulum bundle (r ¼ 0.111 p ¼ 0.005). Both survived FDR
correction. There were also nominally signiﬁcant associations with
the level of the splenium (r ¼ 0.087 p ¼ 0.030) and arcuate
(r ¼ 0.087 p ¼ 0.032) in the same direction, but these did not
survive multiple comparison correction. The corresponding asso-
ciations for tract MD were all nonsigniﬁcant cross-sectionally (all
absolute r values 0.059 p-values 0.138) and longitudinally (all
absolute r values 0.069 p-values 0.158).
4. Discussion
These data represent the ﬁrst large-scale study of longitudinal
S100b concentrations and their association with longitudinal
multimodal brain vascular and neurodegeneration MRI markers in
community-dwelling older adults. We focused on multiple MRIFig. 3. Cross-sectional and longitudinal associations between S100b and white matter tract
WMH for illustration) using MRI data from a single LCB1936 participant. Right panel indica
(cross-sectional at age 73 years; dark blue and dark green) and coupled 3 years change (lon
light green), with standard error bars. Black and red asterisks denote nominal (p < 0.05)
Supplementary Tables A.9 and A.10. Abbreviations: FA, fractional anisotropy; FDR, false disco
of the references to color in this ﬁgure legend, the reader is referred to the Web version ofindices of brain white matter because S100b is predominantly
found in glial cells. We also considered measures of GM and
global atrophy as comparators. Notably, our results suggest that
individual differences in serum S100b concentrations may be
potentially informative for speciﬁc aspects of brain white matter
aging. We found that higher S100b was, in cross-sectional analysis
at age 73 years, signiﬁcantly associated with generally poorer
white matter microstructure (as indexed by gFA), with a small
effect size (Cohen, 1992). Further investigation of tract-speciﬁc
effects indicated that this association is predominantly driven by
lower FA in the anterior thalamic, arcuate, cingulum, and callosal
ﬁbers.
The signiﬁcant gFA-S100b association at age 73 years reported
here contradicts some (van der Leeuw et al., 2017), but corroborates
other (Milleit et al., 2016; Streitbürger et al., 2012) previous cross-
sectional associations in smaller (N  102) samples. Our well-
powered longitudinal design provides important new data on the
coevolution of this serum biomarker with brain MRI, including
several measures that had not previously been examined, such as
white matter MD and markers of SVD. Given the prevalent
expression of S100b in the corpus callosum (Streitbürger et al.,
2012), it is notable that associations between tract-speciﬁc
change and S100b change for both FA and MD in the genu of the
corpus callosum were not signiﬁcant. This merits further investi-
gation in longitudinal samples over a longer period with more
sampling occasions (which could also take account of nonlinear
age-related trajectories).
Although there has been relatively little research on the asso-
ciation between S100b and age-related brain and cognitive decline,microstructure. Left panel shows superior and lateral views of tracts of interest (with
tes the association magnitude (r) for S100b-tract (FA and MD) associations at baseline
gitudinal changes in S100b and microstructure from age 73 to 76 years; light blue and
and FDR-corrected signiﬁcance, respectively. Estimates and p-values are reported in
very rate; MD, mean diffusivity; WMH, white matter hyperintensity. (For interpretation
this article.)
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matter FA could partly be related to deleterious effects due to sys-
temic inﬂammation. Systemic inﬂammatory challenge reportedly
elicits increased BBB permeability in humans and rodent models
(Elwood et al., 2017), and there are relationships between higher
inﬂammatory markers and lower brain metrics, including white
matter markers of SVD (Aribisala et al., 2014; Corlier et al., 2018,
reviewed in; Persson et al., 2014 and in; Wardlaw et al., 2013).
Consequently, it will be of interest to quantify the degree to which
the relationship between inﬂammation and cognitive decline is
mediated by S100b and brain structural outcomes, as well as to
identify the potential genetic and lifestyle determinants of
inﬂammation (e.g., Corlier et al., 2018) in well-powered longitudi-
nal designs. Taken together, our results provide some limited sup-
port for the hypothesis that both (serum markers and brain MRI)
provide meaningful and overlapping biomarkers of age-related
white matter degradation.
This study also provides novel information about the concen-
trations and stability of individual differences in serum S100b (i.e.,
the correlation between samples taken 3 years apart), in generally
healthy older adults. These may suggest that serum S100b con-
centrations in the same individual may represent a relatively stable
trait, although establishing this more robustly would require many
more sampling occasions. We also provide information on sex dif-
ferences in the context of important confounds of age, melanoma,
and dementia. Signiﬁcant associations between greater S100b at
older ages have been reported in some studies (Nygaard et al., 1997;
Schroeter et al., 2011; van Engelen et al., 1992), but were nominally
negative in others (Wiesmann et al., 1998) or null (Portela et al.,
2002). With respect to sex differences, our ﬁnding that females
exhibited higher S100b corroborates the ﬁndings from some
studies (Gazzolo et al., 2003), whereas others report the converse
pattern (Nygaard et al., 1997) or no signiﬁcant difference (Portela
et al., 2002; Streitbürger et al., 2012; Wiesmann et al., 1998; van
der Leeuw et al., 2017). Unlike the present study, those cited pre-
viously were all cross-sectional and represent a mix of single
studies across very wide age ranges (neonate to 70 years old),
across serum and CSF sampling (with varying sensitivity;
Wiesmann et al., 1998), and comprising participants with various
characteristics (healthy controls, mood disorders, those undergoing
diagnostic lumbar puncture, or surgery with spinal anesthesia).
Moreover, as far as the authors are aware, there is no large-scale
data on the stability of individual differences in serum S100b con-
centrations across time in nonpathological older adults. The results
reported here therefore address a substantial gap in our under-
standing of stability and longitudinal S100b trajectories in older
community-dwelling adults.
Although it has been hypothesized that observed increases of
S100b with age could reﬂect (1) age-related increases in myelin
loss, it could also be that (2) CNS cell “turnover” remains stable, but
that cellular S100b concentrations are simply higher (Nygaard et al.,
1997), or that (3) S100b does not change, but that serum concen-
trations are driven by greater age-related BBB leakage. Our ﬁndings
lend some support to the ﬁrst or third interpretations. Nevertheless,
it should be noted that white matter FA can be affected by multiple
microstructural properties, including myelination, but also
extending to axonal bore, cell membranes, microtubules, and other
structures (Beaulieu, 2002; Jones et al., 2013). As such, inferences
about the weak associations of S100b with any speciﬁc micro-
structural property of the brain’s white matter should be under-
taken with caution.
There are several study limitations. We note that our measure of
change is based on a relatively brief (3 years) period. Although older
individuals are at higher risk of brain structural changes than their
younger counterparts, the brief sampling window limits theopportunity for large brain structural changes to take effect, espe-
cially because this group was broadly healthy, but fairly typical of
similarly aged community-dwelling adults in Europe. Further study
with a longer sampling period or a larger sample is merited to in-
crease our ability to reliably assess these potentially subtle coupled
changes, and to account for the likelihood that observed changes
over time are nonlinear. On a related note, our models of latent
change derived from single-indicator latent measures did not allow
for the independent estimation of measurement residuals, meaning
that our measures of change here should be considered as essen-
tially difference scores (not accounting for the covariates). These
analyses at only 2 time points also preclude tests of nonlinear
change and of lead-lag relationships of change in brain and serum
markers. We also reiterate that S100b concentrations may be
inﬂuenced by a number of factors, such as exercise, melanoma,
dementia, sleep apnea, depression, time of year/season, bone
fractures, muscle injury, and burns (Anderson et al., 2001; Chaves
et al., 2010; Harpio and Einarsson, 2004; Koh and Lee, 2014;
Mohammed et al., 2001; Morera-Fumero et al., 2013; Pelinka
et al., 2003; Peskind et al., 2001; Polyakova et al., 2015; Traxdorf
et al., 2016), only some of which (dementia and melanoma) were
accounted for in the present analyses. Our measure of PVS and its
change is likely to be relatively insensitive; the rater could not be
blinded to time, and the binary and disproportionate nature of
visually rated PVS change mean that the estimates reported here
should be interpreted accordingly. Computational methods for PVS
quantiﬁcation that are currently in development (Ballerini et al.,
2016) may improve sensitivity to detect important aging-related
changes. Finally, the narrow age range, ethnic homogeneity (all
participants were White British), and relative good health of study
participants limits the degree to which our ﬁndings can be gener-
alized to groups of different ages, ethnicities, and patients. Never-
theless, the fact that these characteristics obviate such strong
potential confounds in the current analysis can be viewed as an
important strength.
Combined with the large sample size, longitudinal data, rich
multimodal imaging parameters, same-scanner MRI acquisition,
advanced and appropriate statistical modeling, and inclusion of
important covariates, the present study is well-situated to test
hypotheses about cross-sectional and short-term longitudinal as-
sociations between serum S100b and brain structural aging. High
and increasing concentrations of serum S100b at this age is iden-
tiﬁed here as a potentially meaningful marker of poorer brainwhite
matter health and, with further testing, risk of future dementia.
These ﬁndings require replication in other well-powered healthy
and pathological aging samples, and across a longer time period.
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